Chemistry: molecular biology and microbiology – Vector – per se
Patent
1994-07-01
1997-08-05
Guzo, David
Chemistry: molecular biology and microbiology
Vector, per se
4352351, C12N 1586
Patent
active
056541953
ABSTRACT:
A vector which can be used to establish a hybrid SIV/HIV-1 virus is described. This virus can be used to infect an animal such as a monkey to establish an animal model for in vivo testing. This animal model can be used for purposes such as screening for therapeutics, adjuvants and vaccines.
REFERENCES:
Shebata et al. "Generation and Characterization of Infectious Chemeric Clones between Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus from an African Green Monkey", J. Virol., vol. 64, No. 12, Dec. 1990, pp. 5861-5868.
"Monkey-Human Viral Hybrid & New Weapons in AIDS Fight", J. Cohen, Science, vol. 257, Jul. 24, 1992, p. 478.
"Generation of a Chemerica Human and Seman Immunodeficiency Virus Infectious to Monkeys Peripheral Blood Mononuclear cells", Shebata et al. J. Virol, Jul. 1991, pp. 3514-3520.
Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)", Science 220, pp. 868-871.
Gallo et al., "Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS", Science 224, pp. 500-503.
Haseltine et al., "Molecular Biology of the AIDS Virus 1990", Raven Press (1990) pp. 148-152.
Cohen et al., "Identification of a protein encoded by the vpu gene of HIV-1", Nature vol. 334, Aug. 1988, pp. 532-534.
Strebel et al., "A Novel Gene of HIV-1, vpu, and Its 16-Kilodalton Product", Science vol. 241, (1988), pp. 1221-1223.
Thali et al., "Characterization of a Discontinuous Human Immunodeficiency Virus Type 1 gpl20 Epitope Recognized by a Broadly Reactive Neutralizing Human Monoclonal Antibody", Journal of Virology, Nov. 1991, pp. 6188-6193.
Sodroski, et al., "Location of the Trans-Activating Region on the Genome of Human T-Cell Lymphotropic Virus Type III", Science vol. 229, (1985), pp. 74-77.
Dayton et al., "The Trans-Activator Gene of the Human T-Cell Lymphotropic Virus Type III Is Required for Replication", Cell, vol. 44, (1986) pp. 941-947.
Sodroski, et al., "A second post-transcriptional trans-activator gene required for HTLV-III replication", Nature vol. 321 (1986) pp. 412-417.
Sodroski et al., "Replicative and Cytopathic Potential of HTLV-III/LAV with sor Gene Deletions", Science vol. 231, (1986) pp. 1549-1553.
Arya et al., "Trans-Activator Gene of Human T-Lymphotropic Virus Type III (HTLV-III)", Science vol. 229, (1985) pp. 69-73.
Allan et al., "Major Glycoprotein Antigens That Induce Antibodies in AIDS Patients Are Encoded by HTLV-III", Science, vol. 228, (1985) pp. 1091-1093.
Robey et al., "Characterization of Envelope and Core Structural Gene Products of HTLV-III with Sera from AIDS Patients", Science, vol. 228, (1985), pp. 593-595.
Klatzmann et al., "T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV", Nature, vol. 312, (1984) pp. 767-768.
Dalgleish et al., "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus", Nature, vol. 312, (1984) pp. 763-767.
Fisher et al., "A molecular clone of HTLV-III with biological activity", Nature, vol. 316, (1985) pp. 262-266.
Steimer et al., "Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120", Science, vol. 254, (1991) pp. 105-108.
McCune et al., "Suppression of HIV Infection in AZT-Treated SCID-hu Mice", Science, vol. 247, (1990) pp. 564-566.
Posner et al., "An IgG Human Monoclonal Antibody That Reacts With HIV-1/GPl20, Inhibits Virus Binding to Cells and Neutralizes Infection", The Journal of Immunology, vol. 146, (1991) pp. 4325-4332.
McDougal et al., "Binding of the Human Retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) Molecule: Conformation Dependence, Epitope Mapping, Antibody Inhibition, and Potential for Idotypic mimicry", The Journal of Immunology, vol. 137, (1986), pp. 2937-2944.
Gyader, et al., "Genome organization and transactivation of the human immunodeficiency virus type 2", Nature, vol. 326, (1987) pp. 662-669.
Kang et al., "Evidence for non-V3-specific neutralizing antibodies that interfere with gpl20/CD4 binding in human immunodeficiency virus 1-infected humans", Proc. Natl. Acad. Sci. USA., vol. 88, (1991) pp. 6171-6175.
Haseltine William A.
Letvin Norman
Li John
Sodroski Joseph
Conlin David G.
Dana-Farber Cancer Institute
Eisenstein Ronald I.
Guzo David
LandOfFree
Vectors expressing hybrid viruses, methods of use and novel assa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vectors expressing hybrid viruses, methods of use and novel assa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vectors expressing hybrid viruses, methods of use and novel assa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1074343